Other states can draw lessons from 2019 HCA deal, could give AGs more power to regulate sales, strengthen certificate-of-need laws, it notes.
PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with ...
PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceutica ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback